Xenon Pharmaceuticals
Market cap $3.81B 98.3M shares (10-Q, Nov 5, 2026) × $38.78 close Nov 17, 2026
Most recent annual filing: 2026-02-26
- Azetukalner MDD Ph3 topline1Q 2027Azetukalner MDD Ph3 topline, 1Q 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
XEN1701
XEN1120
NBI-921355
Nav1.1 program
XEN1720
- Undisclosed indication
Capital (as filed)
- Cash
- $82.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $868M Sep 30, 2026
- Long-term investments
- $203M Sep 30, 2026
- Operating cash flow
- −$90.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $1.15B cash, runway 2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-10 UPDATE: Xenon Pharmaceuticals (XENE) - The Coin Flip Moves Up 🔒 Paid
- 2026-10-30 UPDATE: Xenon Pharmaceuticals (XENE) - The Nav1.7 Ticket Gets Scratched 🔒 Paid
- 2026-09-17 UPDATE: Xenon Pharmaceuticals (XENE) - The NDA Goes In, The Psychiatry Story Gets a Safety Problem 🔒 Paid
- 2026-08-07 UPDATE: Xenon Pharmaceuticals (XENE) - The Filing Window Opens 🔒 Paid
- 2026-05-02 Xenon Pharmaceuticals (XENE) - Scientific Deep Dive for Azetukalner and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on Xenon Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-02 Buy core Xenon Pharmaceuticals (XENE) - Scientific Deep Dive for Azetukalner and Pipeline Products Azetukalner's de-risked Phase 3 epilepsy data and fortress balance sheet justify the enterprise value, with MDD/BPD as speculative upside options.
- 2026-08-07 Buy core UPDATE: Xenon Pharmaceuticals (XENE) - The Filing Window Opens Completed pre-NDA meeting and reaffirmed Q3 filing keep the highest-probability path to 2027 approval intact, with $1.245B cash eliminating dilution risk.
- 2026-09-17 Hold UPDATE: Xenon Pharmaceuticals (XENE) - The NDA Goes In, The Psychiatry Story Gets a Safety Problem NDA submitted on schedule but voluntary enrollment pause across all psychiatry studies due to neuropsychiatric adverse events adds a new risk axis, reducing conviction on upside while epilepsy fortress remains intact.
- 2026-10-30 Hold UPDATE: Xenon Pharmaceuticals (XENE) - The Nav1.7 Ticket Gets Scratched XEN1701 Phase 1 shows clean cardiac profile with adequate Nav1.7 occupancy, improving pain portfolio optionality, but neither upgrade condition (psychiatry event details nor FDA filing acceptance) has been met.
- 2026-11-10 Hold UPDATE: Xenon Pharmaceuticals (XENE) - The Coin Flip Moves Up X-NOVA2 MDD readout pulled into December 2026 but two upgrade conditions remain unmet; epilepsy thesis intact and $1.15B cash provides no financing pressure around the binary readout.
- Long call · opened May 4, 2026 at $57.40 · -32.4% vs XBI +8.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (9 quotes from 5 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We completed enrollment in the Phase 3 X-NOVA2 study in MDD with approximately 360 total patients; the topline data readout is now expected in December 2026.”
matched to Azetukalner (MDD, X-NOVA2) · topline data
-
-
-
““Following the completion of enrollment in X-NOVA2, we are working toward our first Phase 3 data readout in psychiatry with topline results now expected in December 2026.”
matched to Azetukalner (MDD, X-NOVA2) · topline data
-
-
-
“We remain on track to submit our New Drug Application (NDA) for azetukalner in FOS in the third quarter of 2026, having completed a pre-NDA meeting with the U.S. Food and Drug Administration (FDA).”
matched to Azetukalner · regulatory submission · since happened Sep 17, 2026 / matched to Azetukalner (MDD, X-NOVA2) · topline data -
“Enrollment is ongoing in the Phase 3 X-NOVA2 and X-NOVA3 studies evaluating azetukalner in patients with MDD, with topline data from X-NOVA2 expected in H1 2027.”
matched to Azetukalner (MDD, X-NOVA2) · topline data
-
-
-
““The second quarter of 2026 was marked by strong execution, including a successful pre-NDA meeting, and the NDA submission for azetukalner remains on track for the third quarter of 2026.”
matched to Azetukalner · regulatory submission · since happened Sep 17, 2026 / matched to Azetukalner (MDD, X-NOVA2) · topline data -
““We also remain focused on broadening azetukalner’s opportunity to neuropsychiatry and expect topline Phase 3 X-NOVA2 data in the first half of 2027.”
matched to Azetukalner (MDD, X-NOVA2) · topline data
-
-
-
““The second quarter of 2026 was marked by strong execution, including a successful pre-NDA meeting, and the NDA submission for azetukalner remains on track for the third quarter of 2026.”
matched to Azetukalner · regulatory submission · since happened Sep 17, 2026 -
“Enrollment is ongoing in the Phase 3 X-NOVA2 and X-NOVA3 studies evaluating azetukalner in patients with MDD, with topline data from X-NOVA2 expected in H1 2027.”
matched to Azetukalner (MDD, X-NOVA2) · topline data -
““We also remain focused on broadening azetukalner’s opportunity to neuropsychiatry and expect topline Phase 3 X-NOVA2 data in the first half of 2027.”
matched to Azetukalner (MDD, X-NOVA2) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseXenon Reports Q3 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateX-NOVA2 MDD data moves to December 2026 — the coin flip just got a lot closer — and Xenon quietly announced X-FIRST, a trial designed to push azetukalner into earlier lines of therapy and expand the addressable market well beyond the refractory epilepsy label.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 3, 2026ReleaseXenon to Present at Upcoming Investor Conferences
- Nov 2, 2026ReleaseXenon to Report Q3 2026 Financial Results on November 9, 2026
- Oct 29, 2026ReleaseXenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain→ BD updateXEN1701's Phase 1 data show >75% Nav1.7 receptor occupancy with no cardiovascular signal — the exact selectivity benchmark Big Pharma couldn't crack — while the stock sits -34.5% from its September high on psychiatry fears, making the pain pipeline's first real validation a potentially underappreciated signal.BD extracted 2 program updates from this document → XENE pipeline
- Sep 21, 2026ReleaseXenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
- Sep 17, 2026ReleaseXenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program→ BD updateThe azetukalner NDA is officially in — the epilepsy fortress keeps its walls — but a voluntary enrollment pause in the psychiatry studies due to unexpected neuropsychiatric AEs just made the "free call option" thesis look more complicated than free.BD extracted 1 program update from this document → XENE pipeline
- Sep 3, 2026ReleaseXenon to Present at Wells Fargo Healthcare Conference
- Aug 26, 2026ReleaseXenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026BD extracted 1 program update from this document → XENE pipeline
- Aug 6, 2026ReleaseXenon Reports Q2 2026 Financial Results and Provides Business Update
- Aug 6, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Aug 6, 202610-QQuarterly reportBD extracted 1 program update from this document → XENE pipeline
- Jul 30, 2026ReleaseXenon to Report Q2 2026 Financial Results on August 6, 2026
- Jun 3, 20268-KCurrent report: officer / director change, shareholder vote
- May 7, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Apr 13, 20268-KCurrent report: officer / director change
- Mar 13, 20268-KCurrent report: other events · EX-99.1
- Mar 12, 20268-KCurrent report: material agreement, other events
- Mar 12, 2026424B5Prospectus supplement (offering)
- Mar 11, 2026FWPFree writing prospectus (offering terms)
- Mar 9, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 9, 2026424B5Prospectus supplement (offering)
24 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 9, 2026S-8Employee plan registration→ BD updateSummary on the 8-K
- Nov 6, 2026SCHEDULE 13G/A13G amendment
- Nov 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13G/A13G amendment
- Aug 6, 2026SCHEDULE 13G/A13G amendment
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8 POSEmployee plan registration (post-effective)
- Jun 3, 2026S-8Employee plan registration
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 22, 2026ARSAnnual report to shareholders
- Apr 13, 2026S-8Employee plan registration